We hypothesized that the inhibition of a key enzyme in polyamine biosynthesis with α-difluoromethylornithine (DFMO) will disrupt the DNA repair function of tumor cells and improve the efficacy of PARP inhibitors in HR-competent ovarian cancer cells. The gene discussed is PARP1; the disease is ovarian cancer.